Fleeting activation of ionotropic glutamate receptors sensitizes cortical neurons to complement attack

Neuron

Volumn 36, Issue 3, 2002, Pages 363-374

  Xiong, Zhi Qi ^a   McNamara, James O ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; IONOTROPIC RECEPTOR; REACTIVE OXYGEN METABOLITE;

ARTICLE; ASTROCYTE; BRAIN CELL; CALCIUM TRANSPORT; CELL DEATH; CYTOTOXICITY; HUMAN; NERVE CELL MEMBRANE; PRIORITY JOURNAL; SENSITIZATION;

EID: 0037168111     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(02)00977-7     Document Type: Article

References (34)

1. Asghar S.S., Pasch M.C. Therapeutic inhibition of the complement system. Y2K update. Front. Biosci. 5:2000;E63-E81.
2. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
3. Ciani E., Groneng L., Voltattorni M., Rolseth V., Contestabile A., Paulsen R.E. Inhibition of free radical production or free radical scavenging protects from the excitotoxic cell death mediated by glutamate in cultures of cerebellar granule neurons. Brain Res. 728:1996;1-6.
4. Compston D.A., Morgan B.P., Campbell A.K., Wilkins P., Cole G., Thomas N.D., Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15:1989;307-316.
5. Davoust N., Nataf S., Reiman R., Holers M.V., Campbell I.L., Barnum S.R. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163:1999;6551-6556.
6. Doble A. The role of excitotoxicity in neurodegenerative disease. implications for therapy Pharmacol. Ther. 81:1999;163-221.
7. Dugan L.L., Sensi S.L., Canzoniero L.M., Handran S.D., Rothman S.M., Lin T.S., Goldberg M.P., Choi D.W. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J. Neurosci. 15:1995;6377-6388.
8. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 49:2000;171-186.
9. He X.P., Patel M., Whitney K.D., Janumpalli S., Tenner A., McNamara J.O. Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron. 20:1998;153-163.
10. Huang J., Kim L.J., Mealey R., Marsh H.C. Jr., Zhang Y., Tenner A.J., Connolly E.S. Jr., Pinsky D.J. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science. 285:1999;595-599.
11. Itagaki S., Akiyama H., Saito H., McGeer P.L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645:1994;78-84.
12. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A.J. β-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:1994;5050-5059.
13. Kokmen E., Whisnant J.P., O'Fallon W.M., Chu C.P., Beard C.M. Dementia after ischemic stroke. a population-based study in Rochester, Minnesota (1960-1984) Neurology. 19:1996;154-159.
14. Lafon-Cazal M., Pietri S., Culcasi M., Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature. 364:1993;535-537.
15. Li Q.Y., Pedersen C., Day B.J., Patel M. Dependence of excitotoxic neurodegeneration on mitochondrial aconitase inactivation. J. Neurochem. 78:2001;746-755.
16. Liszewski M.K., Farries T.C., Lublin D.M., Rooney I.A., Atkinson J.P. Control of the complement system. Adv. Immunol. 61:1996;201-283.
17. Matis L.A., Rollins S.A. Complement-specific antibodies. designing novel anti-inflammatories Nat. Med. 1:1995;839-842.
18. Mayer M.M. Mechanism of cytolysis by complement. Proc. Natl. Acad. Sci. USA. 69:1972;2954-2958.
19. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
20. Morgan B.P. Clinical complementology. recent progress and future trends Eur. J. Clin. Invest. 24:1994;219-228.
21. Morgan B.P. Physiology and pathophysiology of complement. progress and trends Crit. Rev. Clin. Lab. Sci. 32:1995;265-298.
22. Morgan B.P. Regulation of the complement membrane attack pathway. Crit. Rev. Immunol. 19:1999;173-198.
23. Oguni H., Andermann F., Rasmussen T.B. The natural history of the syndrome of chronic encephalitis and epilepsy. a study of the MNI series of forty-eight cases Andermann F. Chronic Encephalitis and Epilepsy. 1991;Butterworth-Heinemann, Stoneham, MA. 7-36.pp.
24. Patel M., Day B.J., Crapo J.D., Fridovich I., McNamara J.O. Requirement for superoxide in excitotoxic cell death. Neuron. 16:1996;345-355.
25. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:1994;5477-5484.
26. Scolding N.J., Morgan B.P., Houston W.A., Linington C., Campbell A.K., Compston D.A. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 339:1989;620-622.
27. Shin M.L., Rus H., Niculescu F. Complement system in central nervous system disorders. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;Marcel Dekker Inc, New York. 499-525.pp.
28. Singhrao S.K., Neal J.W., Morgan B.P., Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159:1999;362-376.
29. Vergun O., Sobolevsky A.I., Yelshansky M.V., Keelan J., Khodorov B.I., Duchen M.R. Exploration of the role of reactive oxygen species in glutamate neurotoxicity in rat hippocampal neurones in culture. J. Physiol. 531:2001;147-163.
30. Volicer L., Smith S., Volicer B.J. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 6:1995;258-263.
31. Walport M.J. Complement. N. Engl. J. Med. 344:2001;1058-1066.
32. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
33. Whitney K.D., McNamara J.O. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J. Neurosci. 20:2000;7307-7316.
34. Whitney K.D., Andrews P.I., McNamara J.O. Immunoglobulin G and complement immunoreactivity in the cerebral cortex of Rasmussen's encephalitis patients. Neurology. 53:1999;699-708.